fbpx

August 2017 Newsletter

Could a Cancer Drug Preserve Some Beta Cell Function in Those Newly Diagnosed With Type 1 Diabetes

An early research study suggests that imatinib, which is a drug that suppresses the immune system , may help to preserve some beta cell function in people who are recently diagnosed with Type 1 diabetes. Imatinib, a tyrosine kinase inhibitor, is already approved for use in the treatment of Chronic Myelogenous Leukemia (CML) and several other cancers.

By |2017-08-18T15:00:45-04:00August 17th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|1 Comment

Sneak Preview of New Type 1 Diabetes Research to be Presented at EASD Meeting

The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!

By |2017-08-18T14:59:55-04:00August 16th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments

Type 1 Diabetes Post Meal Insulin Dosing Leads to Poorer Glucose Control

Do you tend to bolus for your meal or snack during or after eating? If so, you may be unwittingly getting in your own way.

By |2017-08-18T15:01:22-04:00August 16th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments

New Benefits Found With Liraglutide Use in Type 1 Diabetes Patients

Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.

By |2017-08-18T15:01:53-04:00August 16th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments

Glucose Concentrations and A1c Levels Vary by Race

Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.

By |2017-08-18T15:02:34-04:00August 16th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments

Encouraging News About Sotagliflozin Use in Type 1 Diabetes

Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).

By |2017-08-18T15:03:20-04:00August 16th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments

ViaCyte Starts Clinical Trial on PEC-Direct Islet Cell Replacement Therapy

Wouldn't it be great if a commercially-available product existed that was derived from stem cells and could effectively replace pancreatic islet cells to allow folks who can't produce endogenous insulin to actually start making it? ViaCyte is working on turning this into a reality someday.

By |2017-08-18T15:04:35-04:00August 15th, 2017|Categories: August 2017 Newsletter, Diabetes Bites|0 Comments
Go to Top